Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial

BACKGROUND: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Trials
Main Authors: Busard, Celine, Menting, Stef, van Bezooijen, Sun-Jine, van den Reek, Juul, Hutten, Barbara, Prens, Errol, de Jong, Elke, van Doorn, Martijn, Spuls, Phyllis
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2017
Assuntos:
Study Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5288945/
https://ncbi.nlm.nih.gov/pubmed/28148280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-1777-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares